Shaolin Capital Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Shaolin Capital Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-125,000	Closed	-$16.3K	–	258
2024 Q4	$16.3K	Sell	125,000 -138,867	-53%	-$17.4K	﹤0.01%	186
2024 Q3	$28.8K	Hold	263,867	–	–	﹤0.01%	157
2024 Q2	$26.4K	Buy	263,867 +73,867	+39%	+$10.1K	﹤0.01%	207
2024 Q1	$28.5K	Hold	190,000	–	–	﹤0.01%	210
2023 Q4	$28.5K	Sell	190,000 -60,000	-24%	-$9.7K	﹤0.01%	254
2023 Q3	$58K	Hold	250,000	–	–	﹤0.01%	294
2023 Q2	$48K	Buy	+250,000	New	+$43.5K	﹤0.01%	383

Shaolin Capital Management's BLACR Position: Q1 2025 in Review

Shaolin Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 125,000 shares — an estimated $16.3K sold.

Shaolin Capital Management first reported a position in BLACR in Q2 2023 and held it in 7 quarters. The position peaked at $58K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Shaolin Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Shaolin Capital Management sold 125,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $16.3K.
Shaolin Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 7 quarters.
Shaolin Capital Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $58K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Shaolin Capital Management's 13F filing for Q1 2025, filed 15 May 2025.